published meta-analysis   sensitivity analysis   studies

Oral antidiabetic drugs in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsAbuhasira, 2021 0.72 [0.23; 2.24] 0.72[0.23; 2.24]Abuhasira, 202110%64moderatenot evaluable clinical improvement (28-day)detailed resultsAbuhasira, 2021 1.70 [0.52; 5.49] 1.70[0.52; 5.49]Abuhasira, 202110%64moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsAbuhasira, 2021 1.22 [0.70; 2.14] 1.22[0.70; 2.14]Abuhasira, 202110%64moderatenot evaluable mechanical ventilationdetailed resultsAbuhasira, 2021 1.62 [0.41; 6.39] 1.62[0.41; 6.39]Abuhasira, 202110%64moderatenot evaluable ICU admissiondetailed resultsAbuhasira, 2021 1.96 [0.51; 7.52] 1.96[0.51; 7.52]Abuhasira, 202110%64moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2022-05-18 01:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1243,925,658,699 - roots T: 290